Article Text

other Versions

PDF
Original article
Neurodevelopmental disorders associated with dosage imbalance of ZBTB20 correlate with the morbidity spectrum of ZBTB20 candidate target genes
  1. Malene B Rasmussen1,
  2. Jakob V Nielsen2,
  3. Charles M Lourenço3,
  4. Joana B Melo4,
  5. Christina Halgren1,
  6. Camila V L Geraldi3,
  7. Wilson Marques Jr3,
  8. Guilherme R Rodrigues3,
  9. Mads Thomassen5,
  10. Mads Bak1,
  11. Claus Hansen1,
  12. Susana I Ferreira6,
  13. Margarida Venâncio7,8,
  14. Karen F Henriksen1,
  15. Allan Lind-Thomsen1,
  16. Isabel M Carreira4,
  17. Niels A Jensen2,
  18. Niels Tommerup1
  1. 1Department of Cellular and Molecular Medicine, Faculty of Health Sciences, Wilhelm Johannsen Centre for Functional Genome Research, University of Copenhagen, Copenhagen, Denmark
  2. 2Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense C, Denmark
  3. 3Neurogenetics Unit, Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-São Paulo, Brazil
  4. 4Laboratório de Citogenética e Genómica and CIMAGO, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
  5. 5Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark
  6. 6Laboratório de Citogenética e Genómica, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
  7. 7Serviço de Genética Médica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  8. 8Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
  1. Correspondence to Professor Niels Tommerup, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, Wilhelm Johannsen Centre for Functional Genome Research, University of Copenhagen, Blegdamsvej 3, 24.4.30, Copenhagen N DK-2200, Denmark; ntommerup{at}sund.ku.dk

Abstract

Background Recently, a number of patients have been described with structural rearrangements at 3q13.31, delineating a novel microdeletion syndrome with common clinical features including developmental delay and other neurodevelopmental disorders (NDD). A smallest region of overlapping deletions (SRO) involved five RefSeq genes, including the transcription factor gene ZBTB20 and the dopamine receptor gene DRD3, considered as candidate genes for the syndrome.

Methods and results We used array comparative genomic hybridization and next-generation mate-pair sequencing to identify key structural rearrangements involving ZBTB20 in two patients with NDD. In a patient with developmental delay, attention-deficit hyperactivity disorder, psychosis, Tourette’s syndrome and autistic traits, a de novo balanced t(3;18) translocation truncated ZBTB20. The other breakpoint did not disrupt any gene. In a second patient with developmental delay and autism, we detected the first microdeletion at 3q13.31, which truncated ZBTB20 but did not involve DRD3 or the other genes within the previously defined SRO. Zbtb20 directly represses 346 genes in the developing murine brain. Of the 342 human orthologous ZBTB20 candidate target genes, we found 68 associated with NDD. Using chromatin immunoprecipitation and quantitative PCR, we validated the in vivo binding of Zbtb20 in evolutionary conserved regions in six of these genes (Cntn4, Gad1, Nrxn1, Nrxn3, Scn2a, Snap25).

Conclusions Our study links dosage imbalance of ZBTB20 to a range of neurodevelopmental, cognitive and psychiatric disorders, likely mediated by dysregulation of multiple ZBTB20 target genes, and provides new knowledge on the genetic background of the NDD seen in the 3q13.31 microdeletion syndrome.

  • Chromosomal
  • Cell biology
  • Cytogenetics
  • Genetics
  • Psychiatry

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.